LivaNova (NASDAQ:LIVN) Hits New 52-Week High – Here’s What Happened

Shares of LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high during trading on Tuesday . The company traded as high as $74.76 and last traded at $74.46, with a volume of 19139 shares traded. The stock had previously closed at $73.64.

Analysts Set New Price Targets

A number of analysts recently commented on LIVN shares. Robert W. Baird lowered their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Mizuho lifted their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Finally, Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Price Performance

The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The firm has a market cap of $4.06 billion, a P/E ratio of 37.90 and a beta of 0.82. The company has a fifty day moving average price of $66.16 and a two-hundred day moving average price of $64.05.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the previous year, the business posted $0.88 EPS. LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current year.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director owned 7,228 shares in the company, valued at $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.35% of the stock is owned by company insiders.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently bought and sold shares of LIVN. Artisan Partners Limited Partnership raised its position in LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after buying an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP raised its position in LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the last quarter. Invesco Ltd. raised its position in LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after buying an additional 902,447 shares during the last quarter. Scopia Capital Management LP acquired a new stake in LivaNova in the 2nd quarter valued at approximately $36,657,000. Finally, Millennium Management LLC raised its position in LivaNova by 22.4% in the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after buying an additional 544,033 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.